Compositions and methods for producing a salty taste in foods or beverages
View Patent ↗The present invention provides compositions containing bitterness inhibitors that reduce the bitter taste of KCl that is used in foods or beverages as a substitute for sodium chloride. The compositions contain as bitterness inhibitors taurine and 5′-adenosinic acid, and 5′-inosinic acid, and/or 5′-guanylic acid. Furthermore, the present invention provides methods of using these compositions and methods for preparing them.
1. A composition comprising a food or beverage comprising (a) potassium chloride in an amount effective to induce a bitter taste and induce a salty taste, (b) taurine or a physiologically acceptable salt thereof, and (c) a 5′-nucleotide monophosphate, comprising 5′-adenosinic acid (AMP), 5′-inosinic acid (IMP) or a physiologically acceptable salt thereof wherein said taurine and said 5′-nucleotide monophosphate are present in an amount effective to reduce the bitter taste of said potassium chloride, and wherein said composition is not seafood and is not an extract of seafood.
2. A composition according to claim 1 , wherein said 5′-nucleotide monophosphate comprises AMP or a physiologically acceptable salt thereof.
3. A composition according to claim 2 , wherein the amount of said AMP or physiologically acceptable salt thereof is between about 100 ppm and about 800 ppm w/w of said food or w/v of said beverage.
4. A composition according to claim 1 , wherein said 5′-nucleotide monophosphate comprises IMP or a physiologically acceptable salt thereof.
5. A composition according to claim 4 , wherein the amount of said IMP or physiologically acceptable salt thereof is up to about 600 ppm w/w of said food or w/v of said beverage.
6. A composition according to claim 1 , wherein said 5′-nucleotide monophosphate comprises a combination of AMP and IMP, or physiologically acceptable salts thereof.
7. A composition according to claim 1 , wherein said 5′-nucleotide monophosphate comprises a combination of AMP, IMP and 5′-guanylic acid (GMP), or physiologically acceptable salts thereof.
8. A composition according to claim 7 , wherein the amount of said potassium chloride is about 0.9%, the amount of said taurine or physiologically acceptable salt thereof is about 750 ppm, the amount of said AMP or physiologically acceptable salt thereof is about 400 ppm, the amount of said IMP or physiologically acceptable salt thereof is about 100 ppm, and the amount of said GMP or physiologically acceptable salt thereof is about 100 ppm, w/w of said food or w/v of said beverage.
9. A composition according to claim 7 , wherein the amount of said potassium chloride is between about 0.5% and about 1.5%, the amount of said taurine or physiologically acceptable salt thereof is between about 400 ppm and about 750 ppm, the amount of said AMP or physiologically acceptable salt thereof is between about 100 ppm and about 800 ppm, the amount of said IMP or physiologically acceptable salt thereof is up to about 600 ppm and the amount of said GMP or physiologically acceptable salt thereof is up to about 600 ppm, w/w of said food or w/v of said beverage.
10. A composition according to claim 1 , wherein said 5′-nucleotide monophosphate consists essentially of AMP, IMP, GMP, combinations thereof or physiologically acceptable salts thereof.
11. A composition according to claim 1 , wherein the amount of said potassium chloride is about 0.9% w/w of said food or w/v of said beverage.
12. A composition according to claim 1 , wherein the amount of said taurine or physiologically acceptable salt thereof is about 750 ppm w/w of said food or w/v of said beverage.
13. A composition according to claim 1 , wherein the amount of said AMP or physiologically acceptable salt thereof is about 600 ppm w/w of said food or w/v of said beverage.
14. A composition according to claim 1 , wherein the amount of said IMP or physiologically acceptable salt thereof is about 200 ppm w/w of said food or w/v of said beverage.
15. A composition according to claim 1 , wherein the amount of said potassium chloride is between about 0.5% and about 1.5% w/w of said food or w/v of said beverage.
16. A composition according to claim 1 , wherein the amount of said taurine or physiologically acceptable salt thereof is between about 400 ppm and about 1200 ppm w/w of said food or w/v of said beverage.
17. A composition according to claim 1 , wherein said food or beverage is chicken broth.
18. A composition according to claim 1 , wherein said food or beverage is beef gravy.
19. A method of reducing sodium intake and increasing potassium intake in the diet of an individual, comprising administering to said individual the composition of claim 1 .
20. A method of preparing the composition of claim 1 , comprising adding to said food or beverage (a) an amount of potassium chloride effective to induce a bitter taste and induce a salty taste, (b) an amount of taurine or physiologically acceptable salt thereof and (c) an amount of a 5′-nucleotide monophosphate wherein said 5′-nucleotide monophosphate comprises AMP, IMP or physiologically acceptable salts thereof, and wherein said amount of taurine and said amount of 5′-nucleotide monophosphate are effective to reduce the bitter taste of said potassium chloride.
21. The method of claim 20 , wherein said 5′-nucleotide monophosphate comprises a combination of AMP and IMP, or physiologically acceptable salts thereof.
22. The method of claim 20 , wherein said 5′-nucleotide monophosphate comprises a combination of AMP, IMP and GMP, or physiologically acceptable salts thereof.
23. A salt substitute consisting essentially of (a) potassium chloride, wherein said potassium chloride is present in an amount effective to induce a bitter taste and induce a salty taste, (b) taurine or physiologically acceptable salt thereof, and (c) a 5′-nucleotide monophosphate comprising AMP, IMP, or a physiologically acceptable salt thereof, wherein said taurine and said 5′-nucleotide monophosphate are present in an amount effective to reduce the bitter taste of said potassium chloride.
24. A salt substitute according to claim 23 , wherein said5′-nucleotide monophosphate comprises AMP or a physiologically acceptable salt thereof.
25. A salt substitute according to claim 23 , wherein said5′-nucleotide monophosphate comprises IMP or a physiologically acceptable salt thereof.
26. A salt substitute according to claim 25 , wherein the amount of said IMP or physiologically acceptable salt thereof is up to about 4% w/w of said salt substitute.
27. A salt substitute according to claim 23 , wherein said5′-nucleotide monophosphate comprises a combination of AMP and IMP, or physiologically acceptable salts thereof.
28. A salt substitute according to claim 27 , wherein the amount of said potassium chloride is about 86.95%, the amount of said taurine or physiologically acceptable salt thereof is about 7.25%, the amount of said AMP or physiologically acceptable salt thereof is about 3.86%, and the amount of said IMP or physiologically acceptable salt thereof is about 1.94%, w/w of said salt substitute.
29. A salt substitute according to claim 23 , wherein said5′-nucleotide monophosphate comprises a combination of AMP, IMP and GMP, or physiologically acceptable salts thereof.
30. A salt substitute according to claim 29 , wherein the amount of said potassium chloride is about 86.95%, the amount of said taurine or physiologically acceptable salt thereof is about 7.25%, the amount of said AMP or physiologically acceptable salt thereof is about 3.86%, the amount of said IMP or physiologically acceptable salt thereof is about 0.97% and the amount of said GMP or physiologically acceptable salt thereof is about 0.97%, w/w of said salt substitute.
31. A salt substitute according to claim 23 , wherein said5′-nucleotide monophosphate consists essentially of AMP, IMP, GMP, combinations thereof or physiologically acceptable salts thereof.
32. A salt substitute according to claim 23 , wherein the amount of said potassium chloride is between about 80% and about 98% w/w of said salt substitute.
33. A salt substitute according to claim 23 , wherein the amount of said taurine or physiologically acceptable salt thereof is between about 2% and about 15% w/w of said salt substitute.
34. A salt substitute according to claim 24 , wherein the amount of said AMP or physiologically acceptable salt thereof is between about 1% and about 8% w/w of said salt substitute.
35. A salt substitute according to claim 23 , wherein the amount of GMP or physiologically acceptable salt thereof is up to about 4% w/w of said salt substitute.
36. A method of reducing sodium intake and increasing potassium intake in the diet of an individual, comprising administering to said individual the composition of claim 23 .
37. A method of preparing the salt substitute of claim 23 , comprising mixing (a) an amount of potassium chloride effective to induce a bitter taste, (b) an amount of taurine or physiologically acceptable salt thereof, and (c) an amount of a 5′-nucleotide monophosphate wherein said 5′-mononucleotide monophosphate comprises AMP, IMP or a physiologically acceptable salt thereof, and wherein said amount of taurine and said amount of 5′-nucleotide monophosphate are effective to reduce the bitter taste of said potassium chloride.
38. The method of claim 37 , wherein said 5′-nucleotide monophosphate comprises a combination of AMP and IMP, or physiologically acceptable salts thereof.
39. The method of claim 37 , wherein said 5′-nucleotide monophosphate comprises a combination of AMP, IMP and GMP, or physiologically acceptable salts thereof.
40. A composition comprising tastands consisting essentially of (a) taurine or physiologically acceptable salt thereof, and (b) a 5′-nucleotide monophosphate selected from the group consisting of AMP, IMP, combinations of AMP and IMP, combinations of AMP, IMP and GMP, and physiologically acceptable salts thereof, wherein said tastands are present in an amount effective to reduce a bitter taste of potassium chloride.
41. A composition according to claim 40 , wherein said5′-nucleotide monophosphate is AMP or a physiologically acceptable salt thereof.
42. A composition according to claim 40 , wherein said5′-nucleotide monophosphate is IMP or a physiologically acceptable salt thereof.
43. A composition according to claim 40 , wherein said5′-nucleotide monophosphate is a combination of AMP and IMP, or physiologically acceptable salts thereof.
44. A composition according to claim 40 , wherein said5′-nucleotide monophosphate is a combination of AMP, IMP and GMP, or physiologically acceptable salts thereof.
45. A composition according to claim 40 , wherein said taurine or physiologically acceptable salt thereof is between about 40% and about 80% w/w of said tastands.
46. A method of reducing sodium intake and increasing potassium intake in the diet of an individual, comprising administering to said individual the composition of claim 40 .
47. A method of preparing the composition of claim 40 , comprising mixing (a) an amount of taurine or physiologically acceptable salt thereof, and (b) a 5′-nucleotide monophosphate selected from the group consisting of AMP, IMP, combinations of AMP and IMP, combinations of AMP, IMP and GMP, and physiologically acceptable salts thereof, and wherein said amount of taurine and said amount of 5′-nucleotide monophosphate are effective to reduce a bitter taste of potassium chloride.
48. The method of claim 47 , wherein said 5′-nucleotide monophosphate comprises a combination of AMP, IMP and GMP, or physiologically acceptable salts thereof. monophosphate comprises a combination of AMP and IMP, or
49. The method of claim 47 , wherein said 5′-nucleotide physiologically acceptable salts thereof.